Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ADPT shares.
View ADPT analyst ratings or view top-rated stocks.

6 analysts have issued twelve-month target prices for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $6.80 in the next year. This suggests a possible upside of 183.3% from the stock's current price.
View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts.

Adaptive Biotechnologies' stock was trading at $4.90 on January 1st, 2024. Since then, ADPT stock has decreased by 51.0% and is now trading at $2.40.
View the best growth stocks for 2024 here.

Adaptive Biotechnologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,100,000 shares, an increase of 7.6% from the March 15th total of 8,460,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the short-interest ratio is presently 6.1 days. Approximately 6.6% of the company's stock are sold short.
View Adaptive Biotechnologies' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ADPT earnings forecast.

Adaptive Biotechnologies will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. The company earned $45.78 million during the quarter, compared to analyst estimates of $50.15 million. Adaptive Biotechnologies had a negative net margin of 132.29% and a negative trailing twelve-month return on equity of 53.65%.

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Amplify Treatments, Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

Adaptive Biotechnologies updated its first quarter 2024 earnings guidance on Tuesday, April, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $41.0 million-$43.0 million, compared to the consensus revenue estimate of $38.2 million.

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

Adaptive Biotechnologies (ADPT) raised $200 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Adaptive Biotechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (4.26%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Egon Durban, Euclidean Capital Llc, Francis Lo, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michelle Renee Griffin, Nitin Sood, R Mark Adams, Stacy L Taylor and Tycho Peterson.
View institutional ownership trends.

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.